Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022

Rhea-AI Summary

Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on August 1, 2022, at 5:00 PM ET to discuss its Q2 2022 financial results and provide revenue guidance for Q3 2022 and the full year. The call will cover recent business developments and financial outlook. Participants can join via webcast or telephone after registration. A replay will be available on Emergent's Investors page.

Emergent focuses on public health threats, developing vaccines and therapeutics, and offering contract development services.

Positive

• Upcoming conference call to discuss Q2 2022 financial results and guidance for Q3 and full year.
• Focus on public health solutions with a mission to protect and enhance life.

Negative

• None.

GAITHERSBURG, Md., July 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, August 1, 2022, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2022, recent business developments, revenue guidance for the third quarter of 2022, and financial outlook for full year 2022.

Conference Call Information
Participants can access the conference call live via webcast from the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the Investors page of Emergent’s website.

About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For over 20 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, Twitter, and Instagram.

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
burrowsr@ebsi.com  

Media Contact:
Matt Hartwig
Senior Director, Media Relations
mediarelations@ebsi.com

FAQ

What date is Emergent BioSolutions' conference call for Q2 2022 earnings?

The conference call is scheduled for August 1, 2022.

What will be discussed in Emergent BioSolutions' upcoming conference call?

The call will cover Q2 2022 financial results, recent business developments, and revenue guidance for Q3 2022 and the full year.

How can I access the conference call by Emergent BioSolutions?

You can access the call via webcast on Emergent's Investors page or register to join by telephone.

What is the focus of Emergent BioSolutions as a company?

Emergent BioSolutions is focused on developing vaccines and therapeutics for public health threats.